JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ)
$252.86 -5.52 (-2.1364%)
Analysed JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ) News Sources
Axsome Begins Phase III Study on Solriamfetol for ADHD in Children
08-07-2026
yahoo.com
3 Value Stocks with Open Questions
16-07-2026
yahoo.com
Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance
16-07-2026
yahoo.com
Apple upgraded, Brinker initiated: Wall Street's top analyst calls
17-07-2026
yahoo.com
Jazz Pharmaceuticals (JAZZ) Refocuses Its Sleep Franchise, Is The Stock Still Cheap?
18-07-2026
yahoo.com
Jazz Pharmaceuticals (JAZZ) Stock Still Looks Like A Bargain After A 119% Run
18-07-2026
yahoo.com
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026
20-07-2026
yahoo.com
Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?
21-07-2026
yahoo.com
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
27-07-2026
yahoo.com
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
28-07-2026
yahoo.com
What is the current price of JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ)?
The current price of JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ) is $252.86.
JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ) absolute price change since previous trading day?
The absolute price change of JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ) since the previous trading day is $-5.52.
JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ) percentage price change since previous trading day?
The percentage price change of JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ) since the previous trading day is -2.1364%.
What is the most recent average sentiment score for JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ)?
The most recent average sentiment score for JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ) is 88 out of 100.
What is the most recent average sentiment for JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ)?
The most recent sentiment for JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ) is .
SEC-8K** Filing Available For JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.